Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

IRVINE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported topline results of a clinical trial of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once-daily) 0.18% formulation, a new formulation of ISTA's ocular, non- steroidal anti-inflammatory agent. The findings demonstrated equivalence between the 0.18% formulation and ISTA's 0.09% formulation of Xibrom given once daily in achieving the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. The data also showed no statistically significant difference between the two formulations in achieving the secondary efficacy endpoints of elimination of ocular pain and mean reduction of markers of inflammation (inflammatory cells and flare). In addition, the results indicated both formulations of bromfenac produced a low overall incidence of ocular adverse events.

"We undertook this trial in connection with our Xibrom QD NDA application, which was submitted to the FDA in December 2007. The nearly identical performance of the two concentrations was unexpected and inconsistent with the previously available data. The results suggest the 0.09% formulation is near the top of the dose-response curve," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "Our next steps are to complete the data analysis and speak with the FDA to determine a possible path forward, as well as consider other options in terms of new Xibrom products. Part of our discussions will be to review the possibility of a label change for the currently marketed 0.09% formulation of Xibrom so that it can be administered once-daily."

Conference Call

ISTA will host a conference call
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...wswire-FirstCall/ -- Ardea Biosciences, Inc.,(Nasd... "RDEA119, a Potent,and Highly Selective MEK1/2 In...SS) -- induced Chronic Colitis in Mice," was prese...ACG) 2008 Annual Meeting in Orlando,Florida. The ...dy of,RDEA119, the Company,s lead mitogen-activate...
(Date:10/6/2008)... /- Pharmasset, Inc.,(Nasda...., is joining the,Company as Vice President of Inv...Smith will be responsible for all investor relatio...ancial Officer Kurt,Leutzinger., Most recently, D...logy,Analyst at JPMorgan Securities, and has been ...
(Date:10/6/2008)... feature children, parents discussing clinical ...., Oct. 6 /PRNewswire-USNewswire/ -- From asthma a...dren saves lives and improves their,health and wel...es of,Health (NIH), "Children and Clinical Studies...h.gov ), offers parents and health,care providers ...
(Date:10/6/2008)...Oct. 6 /- Genaera,Corporati...econd Phase 1,clinical trial of trodusquemine (MSI...tment of type 2 diabetes and obesity. MSI-1436 is ...target that controls the function,of both the lept...ecrease,appetite. In the study, MSI-1436 was found...
Breaking Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4 New discovery leaves blood doping athletes scratching their heads 1667 1 New discovery leaves blood doping athletes scratching their heads 1667 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 1ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 3Genetic variation affects smoking cessation treatment 1663 1Genetic variation affects smoking cessation treatment 1663 2Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 1Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 2
...lyses To Be Presented --, SAN FRANCISCO, April 24,...oday announced that data from the Company,s Phase,...ease will be,presented for the first time in the U...s 59th Annual Meeting in Boston on Thursday,May 3... include new,data from both the mild and moderate ...
...., April 24, 2007 /PRNewswire/ -- Accera Inc.,anno...tudy of its,lead compound AC-1202 in Alzheimer,s d...g of the American Academy of Neurology (AAN) in,Bo...ent of the,program, the data will also be featured...ccera,s vice president of clinical development Dr....
Other Medicine Technology:Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 2Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 3Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ering potentially fatal liver complications from c...y are given before a stem cell transplant// such a...tment. But chemotherapy causes five to 50 per cent...al complication called veno-occlusive disease (VOD...
... was observed that carbohydrates that originate in...ause arthritis.// Researchers from Harvard Medical...ed GAGs to the defense system in the body that cau...s been a mystery, this new finding may shed light ...
...American Journal of Clinical Nutrition it was obse...preventing the build up of plaque in the arteries ...h has shown antioxidant vitamins can protect again...ries. However, most studies have concentrated on p...
...evels of air pollution can trigger a heart attack ... for more than 24 hours. Researchers say that expo...lutants increased the risk of a heart attack by 40...who are most vulnerable are those already at risk ...
Other Medicine News:
Bandeau Bra
Bras and Breast Support
Compression Bra
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication
Medicine Products: